There certainly is an element of risk included. Yet, personally...

There certainly is an element of risk included. Yet, personally I deem it pretty small as the main idea of sozinibercept - that‘s blocking the VEGF-C pathway - holds true for all anti-VEGF-A agents - be it Lucentis, Eylea, Avastin, Beovu or Fabysmo - as they all lead to an unintended upregulation of VEGF-C as the main escape pathway of progressing angionesis.